Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 319

2.
3.

All-cause and potentially disease-related health care costs associated with venous thromboembolism in commercial, Medicare, and Medicaid beneficiaries.

Lefebvre P, Laliberté F, Nutescu EA, Duh MS, LaMori J, Bookhart BK, Olson WH, Dea K, Schein J, Kaatz S.

J Manag Care Pharm. 2012 Jun;18(5):363-74.

4.

Inpatient resource use and cost burden of deep vein thrombosis and pulmonary embolism in the United States.

LaMori JC, Shoheiber O, Mody SH, Bookhart BK.

Clin Ther. 2015 Jan 1;37(1):62-70. doi: 10.1016/j.clinthera.2014.10.024. Epub 2014 Dec 15. Erratum in: Clin Ther. 2015 Oct 1;37(10):2382-3.

PMID:
25524389
5.

Economic burden of deep-vein thrombosis, pulmonary embolism, and post-thrombotic syndrome.

MacDougall DA, Feliu AL, Boccuzzi SJ, Lin J.

Am J Health Syst Pharm. 2006 Oct 15;63(20 Suppl 6):S5-15.

PMID:
17032933
6.
7.

Recurrent hospitalization and healthcare resource use among patients with deep vein thrombosis and pulmonary embolism: findings from a multi-payer analysis.

Lang K, Patel AA, Munsell M, Bookhart BK, Mody SH, Schein JR, Menzin J.

J Thromb Thrombolysis. 2015 May;39(4):434-42. doi: 10.1007/s11239-014-1108-z.

8.

Daily hospitalization costs in patients with deep vein thrombosis or pulmonary embolism treated with anticoagulant therapy.

Dasta JF, Pilon D, Mody SH, Lopatto J, Laliberté F, Germain G, Bookhart BK, Lefebvre P, Nutescu EA.

Thromb Res. 2015 Feb;135(2):303-10. doi: 10.1016/j.thromres.2014.11.024. Epub 2014 Dec 4.

9.

Cost of venous thromboembolism following major orthopedic surgery in hospitalized patients.

Ollendorf DA, Vera-Llonch M, Oster G.

Am J Health Syst Pharm. 2002 Sep 15;59(18):1750-4.

PMID:
12298113
10.
11.

Incidence of hospital readmission in patients diagnosed with DVT and PE: clinical burden of recurrent events.

Nutescu EA, Crivera C, Schein JR, Bookhart BK.

Int J Clin Pract. 2015 Mar;69(3):321-7. doi: 10.1111/ijcp.12519. Epub 2014 Nov 14.

12.

Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.

Menzin J, Korn JR, Cohen J, Lobo F, Zhang B, Friedman M, Neumann PJ.

J Manag Care Pharm. 2010 May;16(4):264-75.

13.

Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.

Laliberté F, Bookhart BK, Vekeman F, Corral M, Duh MS, Bailey RA, Piech CT, Lefebvre P.

J Manag Care Pharm. 2009 May;15(4):312-22.

14.

Economic burden in direct costs of concomitant chronic obstructive pulmonary disease and asthma in a Medicare Advantage population.

Blanchette CM, Gutierrez B, Ory C, Chang E, Akazawa M.

J Manag Care Pharm. 2008 Mar;14(2):176-85.

15.
16.

Use of managed care claims data in the risk assessment of venous thromboembolism in outpatients.

Russell MW, Taylor DC, Cummins G, Huse DM.

Am J Manag Care. 2002 Jan;8(1 Suppl):S3-9.

17.

Actuarial analysis of private payer administrative claims data for women with endometriosis.

Mirkin D, Murphy-Barron C, Iwasaki K.

J Manag Care Pharm. 2007 Apr;13(3):262-72.

18.

Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.

Huse DM, Cummins G, Taylor DC, Russell MW.

Am J Manag Care. 2002 Jan;8(1 Suppl):S10-6.

19.

Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates.

Mahan CE, Borrego ME, Woersching AL, Federici R, Downey R, Tiongson J, Bieniarz MC, Cavanaugh BJ, Spyropoulos AC.

Thromb Haemost. 2012 Aug;108(2):291-302. doi: 10.1160/TH12-03-0162. Epub 2012 Jun 28.

PMID:
22739656
20.

Economic and utilization outcomes associated with choice of treatment for venous thromboembolism in hospitalized patients.

Knight KK, Wong J, Hauch O, Wygant G, Aguilar D, Ofman JJ.

Value Health. 2005 May-Jun;8(3):191-200.

Items per page

Supplemental Content

Write to the Help Desk